Global Pharma may suspend production of vital drugs for Russia
Global pharmaceutical producers are considering suspending of production of vital drugs for the Russian market, due to their unprofitability, caused by devaluation of national currency - the rouble - and the inability to increase of prices.
According to data from the DSM Group, one of Russia’s leading analyst agencies in the local pharmaceutical market, at present vital drugs account for 34.3% of the Russian pharmaceutical market, of which about 77.5 % account for imports in value terms.
At present, prices for vital drugs in Russia are regulated by the Russian Ministry of Health in coordination with the Federal Tariff Service (FTS), which have not allowed foreign pharmaceutical producers to increase prices since 2010.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze